Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Awad received his MD and PhD from the Johns Hopkins School of Medicine in 2008. He completed his residency and chief residency in internal medicine at the Massachusetts General Hospital. He received his fellowship training in medical oncology at the Dana-Farber/ Partners CancerCare program and joined the faculty in the Lowe Center for Thoracic Oncology at Dana-Farber in 2014. His research focuses on understanding mechanisms of response and resistance to immunotherapy in lung cancer and mesothelioma, and he is involved in developing novel therapies for lung cancers with mutations in genes such as MET, RET, ALK, and ROS1.
Immunotherapies and Vaccine Development
Dr. Awad's main area of research is on cancer immunotherapy and vaccine development. He has been working with a number of laboratories to study the genetics and immune microenvironemnt of lung tumors in order to develop better immune therapies for cancer patients. In addition, he conducts research on cancers whose growth is driven by mutations in genes such as RET, ROS1, and ALK, and he has been working to understand how these cancers acquire resistance to targeted therapies.
Dana-Farber Cancer Institute450 Brookline AvenueBoston MA, 02215Get Directions